V-LF-Spiro3D Low and very-low-field 3D magnetic resonance spirometry for advanced regional exploration of respiratory diseases
- Coordinator
- Universite Paris-Saclay, France
- Runs
- 1 April 2023 to 31 March 2027
- Status
- Running
- EU funding
- €3.6m
- Total cost
- €3.6m
- Partners
- 16 organisations in 4 countries
- Type
- European Innovation Council
- Grant agreement
- 101099934
What the project is doing
In the project's own words, from its summary on CORDIS.
Lung function is a central concern in the fight against covid-19. Beyond the pandemic heavy losses and long-term health implications, respiratory diseases represent a major threat for the World Health Organisation. It is one of the leading causes of death worldwide, associated to our way of living and impacting all of society. Current tools for diagnosing and monitoring pulmonary conditions are hindered by poor sensitivity (lung function tests), radiation exposure (computed tomography) or examination cost (magnetic resonance imaging, MRI).
They all differently fail to fully assess lung structure and functionV|LF-Spiro3D aims at democratizing newly developed and breakthrough 3D MR spirometry with high performance, low-cost MRI techniques to provide a ten-minute morphofunctional MRI protocol to engage patients in a safer, easier and more comfortable way. Based on recent works at Universities Paris-Saclay and Aberdeen, in collaboration with leading MR manufacturer Siemens, SME NMR Service, major French-Dutch hospitals and patient organisations, V|LF-Spiro3D brings together multidisciplinary experts in a patient-oriented approach for both adults and childrenV|LF-Spiro3D will redesign current MRI architecture to perform 3D MR spirometry at low and very low field.
High-performance MRI hardware will be developed with accelerated acquisitions and coupled reconstruction strategies relying on deep learning. Biomechanical lung modelling and deep data processing will be guided by implementation of 3D MR spirometry in clinical facilities to produce unprecedentedly large sets of normative and training data covering six major respiratory diseasesBy prioritizing both technology transfer and innovation, V|LF-Spiro3D aims to build up a one-stop-shop imaging standard for unrestricted assessment of lung pathophysiology.
The impacts are expected to yield benefits beyond lung imaging and boost health deep-tech on point-of-care imaging and multi-parameter-based digital health in the EU
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universite Paris-Saclay | Gif-Sur-Yvette | France | Coordinator |
| Nmr Service GmbH | Erfurt | Germany | Participant |
| Assistance Publique Hopitaux De Paris | Paris | France | Participant |
| Association Hopital Foch | Suresnes Cedex | France | Participant |
| Centre National De La Recherche Scientifique CNRS | Paris | France | Third party |
| Commissariat a L Energie Atomique Et Aux Energies Alternatives | Paris | France | Third party |
| Ecole Polytechnique | Palaiseau Cedex | France | Third party |
| Institut Mines-Telecom | Palaiseau | France | Third party |
| Institut National De La Sante Et De La Recherche Medicale | Paris | France | Third party |
| Institut National De Recherche En Informatique Et Automatique | Le Chesnay Cedex | France | Third party |
| Institut Polytechnique De Paris | Palaiseau | France | Participant |
| Pole De Ressources En Education Therapeutique Du Patient Ile De France | Paris | France | Participant |
| Siemens Healthcare SAS | Courbevoie | France | Participant |
| Erasmus Universitair Medisch Centrum Rotterdam | Rotterdam | Netherlands | Participant |
| Tilburg University- Universiteit Van Tilburg | Tilburg | Netherlands | Participant |
| The University Court of the University of Aberdeen | Aberdeen | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI